hMTH1

8-Br-dGTP (8-Bromo-dGTP) sodium (Compound 5), an 8-brominated purine nucleotide, is a syn-oriented analog of dGTP. 8-Br-dGTP sodium can be hydrolyzed by the enzyme hMTH1 protein (HY-P74740). 8-Br-dGTP sodium inhibits dGTP-activated ADP reduction with a K_i of 56  μM. 8-Br-dGTP sodium has no significant genotoxicity and mutagenic potentials during DNA synthesis ^[1] .

8-Oxo-dGTP (8-Oxo-Deoxyguanosine triphosphate) trisodium solution (100mM) is an oxidized guanine nucleotide formed by ROS-mediated oxidative modification of dGTP, and it also serves as a key substrate for 8-oxo-dGTP pyrophosphohydrolases (such as hMTH1 and E. coli MutT). 8-Oxo-dGTP trisodium solution (100mM) acts as a DNA mutagen, inserts into nascent DNA and pairs with adenine and cytosine, inducing A:T to C:G transversion mutations. Furthermore, 8-Oxo-dGTP trisodium solution (100mM) causes oxidative DNA base modification, strand breakage and S-phase arrest, and ultimately triggers AIF-mediated apoptosis and promotes spontaneous carcinogenesis in mth1-deficient mice. Accumulation of 8-Oxo-dGTP trisodium solution (100mM) in cells induces genomic instability, but it exhibits a tumor-suppressive effect that reduces tumor incidence in mouse models instead. 8-Oxo-dGTP trisodium solution (100mM) is widely used in studies related to spontaneous carcinogenesis, Parkinson's disease, Alzheimer's disease, heart failure and tumor mechanisms ^[1] .